The Pan Am Cancer Treatment Center, an institution committed to provide the latest, groundbreaking immunotherapies to patients battling cancer, recently announced the availability of ImmunoMax, a plant-derived, pharmaceutical grade polysaccharide that has demonstrated its ability to boost the activity of the body’s natural killer cells. The treatment is now available to advanced cancer patients who meet inclusion criteria.
ImmunoMax is not a new drug, however, as it has been approved in Russia for the past 13 years as a treatment against viral and bacterial infections, and has been reported to reduce PSA levels in prostate cancer patients.
“It is well known that many cancer patients have suppressed natural killer cell activity as compared to healthy controls, studies have demonstrated that patients with low natural killer cell activity have a poorer prognosis as compared to patients with higher natural killer cell activity (3-5),” said Dr. Javier Lopez, Chief Executive Officer of the Pan Am Cancer Treatment Center. “Efficacy of numerous cancer therapies offered by oncologists such as Herceptin (6,7), Rituximab (8), and Cetuximab (9), has been shown to depend on activity of the patient’s natural killer cells. It is conceivable that utilization of ImmunoMax by itself, or in combination with existing therapies may be of benefit to cancer patients.”
A joint team of researchers from the University of California Irvine, the Institute for Molecular Medicine, and the Gamaley Research Institute of the Russian Ministry of Health, published a paper in the Journal of Translational Medicine titled “Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, ImmunoMax®, as a therapeutic strategy for metastatic breast cancer“, on ImmunoMax’s ability to stimulate dendritic cells along with natural killer cells. The study was also successful in demonstrating a noticeable suppression of breast cancer growth and spread in a higher aggressive animal model.
“In an age where the promise of cancer immunotherapy has the medical community electrified with positive results from trials using checkpoint inhibitors and CAR-T cells, it is important to remember that the innate immune system is critical both to initiation of antitumor immunity, as well as maintenance of the immune response and establishment of immunological memory,” said Dr. Julio Selva Pallares, Medical Director of the Pan Am Cancer Treatment Center. “We are proud to begin offering, to patients that fit the criteria, access to ImmunoMax, which in our opinion is a highly promising immune stimulatory therapeutic.”
“In my opinion, after 13 years of using ImmunoMax as an immune stimulant in Russia and CIS countries as an approved pharmaceutical drug, I believe that we are adding a potent weapon in the arsenal of the Pan Am Cancer Treatment Center,” said Dr. Ravshan Ataullakhanov, MD, Ph.D, DSc, inventor of ImmunoMax and Professor of Immunology at the Institute of Immunology and Lomonosov Moscow State University.